Remedium Bio
Massachusetts, USA Space Gene therapy to combat osteoarthritis
Challenge
~500 million people worldwide who are affected by osteoarthritis
There are an estimated 500 million people worldwide who are affected by osteoarthritis, a disease which can cause excruciating pain and make everyday tasks difficult or impossible.
Solution
AAV vector to induce expression of clinically validated proteins to target osteoarthritis
Remedium Bio is developing a gene therapy asset which utilizes an FDA-approved AAV vector to induce expression of clinically validated proteins to target mild-moderate osteoarthritis.
Impact
USD 20B market
Remedium Bio is aiming to capture the USD 20B mild-moderate osteoarthritis market, which currently has no FDA-approved therapies.
“[The company has a] efficient approach to product development – modular application of proven technologies for the treatment of well characterized pathologies, with a focus on its lead candidate gene therapy, the only single-injection treatment potentially capable of increasing cartilage thickness in Osteoarthritic joints."
Frank Luppino (CEO of Remedium Bio)
| In the News |
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.